SCHEMBL4287595

SCHEMBL4287595

Cc1cc(C(=O)Nc2nccs2)ccc1NC(=O)C1CCCC1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.62
ADORA1 P30542 4/20 0.62
RAB9A P51151 6/20 0.54
NPC1 O15118 6/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
MAPK1 P28482 2/20 0.52
USP2 O75604 1/20 0.52
LMNA P02545 1/20 0.52
MAPK14 Q16539 1/20 0.52
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
ESR2 Q92731 1/20 0.51
HSD17B10 Q99714 1/20 0.51
ALDH1A1 P00352 2/20 0.51
RXFP1 Q9HBX9 1/20 0.50
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289814 0.87 ADORA2A (0.61) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4286514 0.87 ADORA2A (0.61) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4289116 0.87 RAB9A (0.54) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
Cycloheptane SCHEMBL5501371 0.85 ADORA2A (0.69) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4290407 0.84 ADORA2A (0.68) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4293208 0.82 SMN1; SMN2 (0.65) ADORA2ARAB9ANPC1SMN1; SMN2MEN1
SCHEMBL17404960 0.79 NPC1 (0.68) NPC1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL1119373 0.78 RAB9A (0.71) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL8013302 0.78 NPC1 (0.67) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL4293148 0.78 ADORA2A (0.74) ADORA2AADORA1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US claimed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP claimed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP claimed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US claimed
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885RAB9A 2380/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885RAB9A 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.